SCHOTT PHARMA AG& CO KGAA (1SXP.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:1SXP - DE000A3ENQ51 - Common Stock
19.12 EUR
+0.22 (+1.16%)
Overall 1SXP gets a fundamental rating of 6 out of 10. We evaluated 1SXP against 19 industry peers in the Life Sciences Tools & Services industry. While 1SXP has a great profitability rating, there are some minor concerns on its financial health. 1SXP is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
1SXP had positive earnings in the past year.
1SXP had a positive operating cash flow in the past year.
1SXP had positive earnings in each of the past 5 years.
1SXP had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
1SXP has a Return On Assets of 9.61%. This is amongst the best in the industry. 1SXP outperforms 89.47% of its industry peers.
Looking at the Return On Equity, with a value of 17.02%, 1SXP belongs to the top of the industry, outperforming 89.47% of the companies in the same industry.
With an excellent Return On Invested Capital value of 13.92%, 1SXP belongs to the best of the industry, outperforming 89.47% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for 1SXP is significantly above the industry average of 9.25%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.61% | ||
| ROE | 17.02% | ||
| ROIC | 13.92% |
ROA(3y)11.06%
ROA(5y)11.96%
ROE(3y)19.55%
ROE(5y)21.48%
ROIC(3y)15.68%
ROIC(5y)17.03%
1.3 Margins
The Profit Margin of 1SXP (15.06%) is better than 84.21% of its industry peers.
1SXP's Profit Margin has been stable in the last couple of years.
1SXP's Operating Margin of 19.46% is fine compared to the rest of the industry. 1SXP outperforms 78.95% of its industry peers.
In the last couple of years the Operating Margin of 1SXP has grown nicely.
1SXP's Gross Margin of 33.73% is on the low side compared to the rest of the industry. 1SXP is outperformed by 68.42% of its industry peers.
In the last couple of years the Gross Margin of 1SXP has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 19.46% | ||
| PM (TTM) | 15.06% | ||
| GM | 33.73% |
OM growth 3Y3.98%
OM growth 5YN/A
PM growth 3Y0.22%
PM growth 5YN/A
GM growth 3Y-1.12%
GM growth 5YN/A
2. Health
2.1 Basic Checks
1SXP has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for 1SXP remains at a similar level compared to 1 year ago.
Compared to 1 year ago, 1SXP has a worse debt to assets ratio.
2.2 Solvency
1SXP has a debt to FCF ratio of 1.72. This is a very positive value and a sign of high solvency as it would only need 1.72 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 1.72, 1SXP belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
1SXP has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
1SXP has a Debt to Equity ratio of 0.09. This is amongst the best in the industry. 1SXP outperforms 94.74% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 1.72 | ||
| Altman-Z | N/A |
ROIC/WACC1.69
WACC8.24%
2.3 Liquidity
A Current Ratio of 1.57 indicates that 1SXP should not have too much problems paying its short term obligations.
The Current ratio of 1SXP (1.57) is better than 78.95% of its industry peers.
A Quick Ratio of 1.17 indicates that 1SXP should not have too much problems paying its short term obligations.
With a decent Quick ratio value of 1.17, 1SXP is doing good in the industry, outperforming 73.68% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.57 | ||
| Quick Ratio | 1.17 |
3. Growth
3.1 Past
The earnings per share for 1SXP have decreased by -3.00% in the last year.
1SXP shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 14.04% yearly.
1SXP shows a small growth in Revenue. In the last year, the Revenue has grown by 2.86%.
1SXP shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.84% yearly.
EPS 1Y (TTM)-3%
EPS 3Y14.04%
EPS 5YN/A
EPS Q2Q%-3.23%
Revenue 1Y (TTM)2.86%
Revenue growth 3Y13.84%
Revenue growth 5YN/A
Sales Q2Q%1.13%
3.2 Future
The Earnings Per Share is expected to grow by 11.14% on average over the next years. This is quite good.
1SXP is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.59% yearly.
EPS Next Y3.25%
EPS Next 2Y8.71%
EPS Next 3Y10.5%
EPS Next 5Y11.14%
Revenue Next Year2.31%
Revenue Next 2Y5.51%
Revenue Next 3Y7.02%
Revenue Next 5Y7.59%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 19.71 indicates a rather expensive valuation of 1SXP.
1SXP's Price/Earnings ratio is a bit cheaper when compared to the industry. 1SXP is cheaper than 78.95% of the companies in the same industry.
1SXP's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.31.
Based on the Price/Forward Earnings ratio of 16.34, the valuation of 1SXP can be described as correct.
1SXP's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. 1SXP is cheaper than 78.95% of the companies in the same industry.
1SXP is valuated cheaply when we compare the Price/Forward Earnings ratio to 36.56, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.71 | ||
| Fwd PE | 16.34 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, 1SXP is valued a bit cheaper than 73.68% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, 1SXP is valued a bit more expensive than the industry average as 73.68% of the companies are valued more cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 57.27 | ||
| EV/EBITDA | 10.98 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
1SXP has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)6.07
PEG (5Y)N/A
EPS Next 2Y8.71%
EPS Next 3Y10.5%
5. Dividend
5.1 Amount
With a yearly dividend of 0.85%, 1SXP is not a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 0.70, 1SXP pays a bit more dividend than its industry peers.
With a Dividend Yield of 0.85, 1SXP pays less dividend than the S&P500 average, which is at 2.32.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.85% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
1SXP pays out 16.40% of its income as dividend. This is a sustainable payout ratio.
DP16.4%
EPS Next 2Y8.71%
EPS Next 3Y10.5%
FRA:1SXP (11/28/2025, 7:00:00 PM)
19.12
+0.22 (+1.16%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners19.52%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.88B
Revenue(TTM)975.68M
Net Income(TTM)146.90M
Analysts78.95
Price Target29.58 (54.71%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.85% |
Yearly Dividend0.15
Dividend Growth(5Y)N/A
DP16.4%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.21%
Min EPS beat(2)-1.05%
Max EPS beat(2)5.48%
EPS beat(4)1
Avg EPS beat(4)-5.25%
Min EPS beat(4)-14.42%
Max EPS beat(4)5.48%
EPS beat(8)4
Avg EPS beat(8)6.65%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.26%
Min Revenue beat(2)-2.27%
Max Revenue beat(2)1.75%
Revenue beat(4)1
Avg Revenue beat(4)-2.21%
Min Revenue beat(4)-5.31%
Max Revenue beat(4)1.75%
Revenue beat(8)3
Avg Revenue beat(8)0.96%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.82%
PT rev (3m)-1.05%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-1.65%
EPS NY rev (3m)-1.33%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-0.3%
Revenue NY rev (3m)-1.08%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.71 | ||
| Fwd PE | 16.34 | ||
| P/S | 2.95 | ||
| P/FCF | 57.27 | ||
| P/OCF | 14.14 | ||
| P/B | 3.34 | ||
| P/tB | 3.45 | ||
| EV/EBITDA | 10.98 |
EPS(TTM)0.97
EY5.07%
EPS(NY)1.17
Fwd EY6.12%
FCF(TTM)0.33
FCFY1.75%
OCF(TTM)1.35
OCFY7.07%
SpS6.48
BVpS5.73
TBVpS5.53
PEG (NY)6.07
PEG (5Y)N/A
Graham Number11.18
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.61% | ||
| ROE | 17.02% | ||
| ROCE | 17.02% | ||
| ROIC | 13.92% | ||
| ROICexc | 14.45% | ||
| ROICexgc | 14.86% | ||
| OM | 19.46% | ||
| PM (TTM) | 15.06% | ||
| GM | 33.73% | ||
| FCFM | 5.15% |
ROA(3y)11.06%
ROA(5y)11.96%
ROE(3y)19.55%
ROE(5y)21.48%
ROIC(3y)15.68%
ROIC(5y)17.03%
ROICexc(3y)16.18%
ROICexc(5y)17.77%
ROICexgc(3y)16.78%
ROICexgc(5y)18.78%
ROCE(3y)19.2%
ROCE(5y)20.87%
ROICexgc growth 3Y-8.59%
ROICexgc growth 5YN/A
ROICexc growth 3Y-7.46%
ROICexc growth 5YN/A
OM growth 3Y3.98%
OM growth 5YN/A
PM growth 3Y0.22%
PM growth 5YN/A
GM growth 3Y-1.12%
GM growth 5YN/A
F-Score5
Asset Turnover0.64
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 1.72 | ||
| Debt/EBITDA | 0.3 | ||
| Cap/Depr | 203.46% | ||
| Cap/Sales | 15.71% | ||
| Interest Coverage | 11.82 | ||
| Cash Conversion | 76.76% | ||
| Profit Quality | 34.23% | ||
| Current Ratio | 1.57 | ||
| Quick Ratio | 1.17 | ||
| Altman-Z | N/A |
F-Score5
WACC8.24%
ROIC/WACC1.69
Cap/Depr(3y)291.84%
Cap/Depr(5y)279.9%
Cap/Sales(3y)17.77%
Cap/Sales(5y)16.62%
Profit Quality(3y)26.98%
Profit Quality(5y)27.79%
High Growth Momentum
Growth
EPS 1Y (TTM)-3%
EPS 3Y14.04%
EPS 5YN/A
EPS Q2Q%-3.23%
EPS Next Y3.25%
EPS Next 2Y8.71%
EPS Next 3Y10.5%
EPS Next 5Y11.14%
Revenue 1Y (TTM)2.86%
Revenue growth 3Y13.84%
Revenue growth 5YN/A
Sales Q2Q%1.13%
Revenue Next Year2.31%
Revenue Next 2Y5.51%
Revenue Next 3Y7.02%
Revenue Next 5Y7.59%
EBIT growth 1Y12.08%
EBIT growth 3Y18.37%
EBIT growth 5YN/A
EBIT Next Year46.93%
EBIT Next 3Y24.15%
EBIT Next 5Y18.79%
FCF growth 1Y-27.75%
FCF growth 3Y33.55%
FCF growth 5YN/A
OCF growth 1Y-5.4%
OCF growth 3Y19.45%
OCF growth 5YN/A
SCHOTT PHARMA AG& CO KGAA / 1SXP.DE FAQ
Can you provide the ChartMill fundamental rating for SCHOTT PHARMA AG& CO KGAA?
ChartMill assigns a fundamental rating of 6 / 10 to 1SXP.DE.
What is the valuation status of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) stock?
ChartMill assigns a valuation rating of 4 / 10 to SCHOTT PHARMA AG& CO KGAA (1SXP.DE). This can be considered as Fairly Valued.
Can you provide the profitability details for SCHOTT PHARMA AG& CO KGAA?
SCHOTT PHARMA AG& CO KGAA (1SXP.DE) has a profitability rating of 8 / 10.
Can you provide the PE and PB ratios for 1SXP stock?
The Price/Earnings (PE) ratio for SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is 19.71 and the Price/Book (PB) ratio is 3.34.
Is the dividend of SCHOTT PHARMA AG& CO KGAA sustainable?
The dividend rating of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is 3 / 10 and the dividend payout ratio is 16.4%.